Hib vaccine conjugate - Panacea Biotec

Drug Profile

Hib vaccine conjugate - Panacea Biotec

Alternative Names: Haemophilus influenzae type B vaccine - Panacea Biotech; novoHib

Latest Information Update: 03 May 2016

Price : $50

At a glance

  • Originator Panacea Biotec
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilus infections

Most Recent Events

  • 03 May 2016 No recent reports on development identified - Preregistration for Haemophilus infections in Russia (IM)
  • 31 Jul 2012 Hib vaccine conjugate licensed to Binnopharm in Russia
  • 31 Dec 2008 Launched for Haemophilus infections in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top